Table 1.
Characteristics | Total (n = 118) |
---|---|
Age (year) | 62.7 ± 7.8 |
Male sex—no. (%) | 75 (63.6) |
Early recurrences no. (%) | 21 (17.8) |
Paroxysmal AF | 64 (54.2) |
Body mass index (kg/m2) | 32.1 ± 5.0 |
LA volume (ml) | 94.8 ± 34.3 |
Mean CHA2DS2-VASC score | 2.2 ± 1.1 |
Mean HAS-BLED score | 1.4 ± 0.8 |
Hypertension—no. (%) | 92 (80) |
Coronary artery disease = no. (%) | 23 (19.5) |
Diabetes and prediabetes (IGT + IFG) | 27 (22.9) |
Dyslipidemia | 20 (16.9) |
Valvular heart disease | 17 (14.4) |
Thyroid disease | 28 (23.7) |
RR syst (mmHg) | 128.2 ± 11.9 |
RR diast (mmHg) | 80.1 ± 9.1 |
RBC (106/ml) | 4.8 ± 0.5 |
Hb (g/dl) | 15.2 ± 1.3 |
Hct (%) | 45.1 ± 4.4 |
MCV (fl) | 94.0 ± 4.6 |
MCH (pg) | 31.7 ± 1.7 |
MCHC (g/dl) | 34.3 ± 6.3 |
RDW-CV (%) | 12.7 ± 1.1 |
WBC (× 103/ml) | 7 ± 1.6 |
Plt (103/ml) | 207 ± 51.1 |
CRP (mg/l) | 0.3 ± 0.7 |
Chol (mg/dl) | 179.4 ± 48.9 |
HDL (mg/dl) | 60 ± 14.3 |
LDL (mg/dl) | 111.8 ± 43.2 |
TG (mg/dl) | 126.7 ± 62.7 |
Glucose (mg/dl) | 103.1 ± 18.6 |
INR | 1.6 ± 0.7 |
aPTTs | 39.7 ± 8.6 |
Fibrinogen (mg/dl) | 387.4 ± 76 |
D-dimers (µg/ml) | 0.3 ± 0.4 |
Troponin T hs (pg/ml) | 9.8 ± 6.4 |
CPK (U/l) | 142.9 ± 104.6 |
CP-MB (U/l) | 18.2 ± 9.9 |
Na (mmol/l) | 142.1 ± 2.1 |
K (mmol/l) | 4.5 ± 0,4 |
Urea (mg/dl) | 38.7 ± 9.5 |
GFR (MDRD) | 74.0 ± 15.8 |
Creatinine (mg/dl) | 1.0 ± 0.2 |
TSH (uIU/ml) | 2.2 ± 2.3 |
AlAT (U/l) | 27.7 ± 14 |
AspAT (U/l) | 24.7 ± 6.9 |
Medication use—no. (%) | |
NOAC | 82 (69.8) |
Beta blockers | 104 (88.1) |
Statins | 64 (54.2) |
ACE-I | 51 (43.2) |
ACE-I + ARB | 83 (70.3) |
Diuretics | 42 (35.6) |
Smoking | 15 (12.7) |
Continuous data are presented as means with SD. Categorical data are presented as counts with their percentage values in brackets
LV Left ventricle, NOAC novel oral anticoagulants, ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, CHA2DS2-VASc (Congestive Heart failure); hypertension; Age ≥ 75 (doubled); Diabetes; Stroke (doubled); Vascular disease; Age 65–74, Sex (female)